Treatment of joint pain in Crohn's patients with budesonide controlled ileal release

Clinical and Experimental Pharmacology and Physiology

Volumn 27, Issue 4, 2000, Pages 295-298

  Florin, Timothy H J ^a,d   Graffner, Hans ^b   Nilsson, Lars Göran ^b   Persson, Tore ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Astra Draco AB   (Sweden)

^c NONE   (Sweden)

^d MATER ADULT HOSPITAL   (Australia)

Author keywords

Arthritis; Budesonide controlled ileal release; Crohn's; Joint pain; Mucosal immunology

Indexed keywords

BUDESONIDE; PREDNISONE;

ADRENAL SUPPRESSION; ARTHRALGIA; ARTICLE; CONTROLLED RELEASE FORMULATION; CROHN DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; HUMAN; MAJOR CLINICAL STUDY; REMISSION;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADRENAL GLANDS; ANTI-INFLAMMATORY AGENTS; ARTHRALGIA; BUDESONIDE; CROHN DISEASE; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; ILEUM; MALE; MULTICENTER STUDIES; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0034036711     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2000.03238.x     Document Type: Article

References (14)

1. 1. Greenberg G, Feagan B, Martin F et al. Oral budesonide for active Crohn's disease. N. Engl. J. Med. 1994; 331: 836-41.
2. 2. Rutgeerts P, Löfberg R, Malchow H et al. A comparison of budesonide with prednisolone for active Crohn's disease. N. Engl. J. Med. 1994; 331: S42-5.
3. 3. Campieri M, Ferguson A, Doe W et al. Oral budesonide competes favorably with prednisolone in active Crohn's disease. Gastroenterology 1995; 108: A790.
4. 4. Thalén A, Brattsand R. Synthesis and anti-inflammatory properties of budesonide, a new non-halogenated glucocorticoid with high local activity. Arzneimittel Forschung 1979; 29: 1687-90.
5. 5. Brattsand R. Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Can. J. Gastroenterol. 1990; 4: 407-14.
6. 6. Gravallese EM, Kantrowitz FG. Arthritic manifestations of inflammatory bowel disease. Am. J. Gastroenterol. 1988; 83: 703-9.
7. 7. Schorr-Lesnick B, Brandt LJ. Selected rheumatologic and dermatologic manifestations of inflammatory bowel disease. Am. J. Gastroenterol. 1988; 83: 216-23.
8. 8. Retsky JE, Kraft SC. The extraintestinal manifestations of inflammatory bowel disease. In: Kirsner JB, Shorter RG (eds). Inflammatory Bowel Disease, 4th edn. Williams & Wilkins, Baltimore. 1995; 474-91.
9. 9. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: Their particular distribution and natural history. Gut 1998; 42: 387-91.
10. 10. De Vos M, Mielants H, Cuvelier C, Elewaut A, Veys E. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 1996; 110: 1696-703.
11. 11. Sanderson IR, Boulton P, Menzies I, Walker-Smith JA. Improvement of abnormal lactulose/rhamnose permeability in active Crohn's disease of the small bowel by an elemental diet. Gut 1987; 28: 1073-6.
12. 12. Warshaw AL, Walker WA, Isselbacher KJ. Protein uptake by the intestine: Evidence for absorption of intact macromolecules. Gastroenterology 1974; 66: 987-92.
13. 13. Edsbäcker S, Larsson P, Nilsson M, Wiren J-E. Budesonide controlled ileal release (CIR) affects plasma cortisol less than prednisolone. Gastroenterology 1995; 108: A814.
14. 14. Naber AHJ, Olaison G, Smedh K, Jansen JBMJ, Sjodahl R. Pharmacokinetics of budesonide controlled ileal release capsules in active Crohn's disease. Gastroenterology 1996; 110: A977.